戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ensory neurons express messenger RNA for the P2X3 receptor.
2 latability of potential analgesics targeting P2X3 receptors.
3  responsible for the potency drop in primate P2X3 receptors.
4 express TRPV1, bradykinin B2, and purinergic P2X3 receptors.
5 ors, and enhanced the expression of P2X2 and P2X3 receptors.
6 ochemically stained with an antibody against P2X3 receptors.
7 p, 11, was also very potent at both P2X1 and P2X3 receptors.
8 e, 10, was 28-fold selective for P2X1 versus P2X3 receptors.
9 with activation of the rapidly desensitising P2X3 receptors.
10 tivation of nociceptive fibres which possess P2X3 receptors.
11  phenomena are normalized by the blockade of P2X3 receptors.
12 .03) but was significantly higher (0.07) for P2X3 receptors.
13           In contrast, the expression of the P2X3 receptor, a marker for non-peptidergic nerve fibers
14 ATP in a manner dependent on P2Y1, P2Y2, and P2X3 receptor activation.
15 ndogenously active CaMKII up-regulates basal P2X3 receptor activity in dorsal root ganglion neurons.
16                                Antagonism of P2X3 receptors also reduces arterial pressure and basal
17 s of 5 mM at the P2X2 receptor, 89 mM at the P2X3 receptor and 15 mM at both the P2X2/3 heteromeric r
18 s probably due to co-expression of homomeric P2X3 receptors and heteromeric receptors comprising P2X3
19                            Here we present a P2X3 receptor antagonist, eliapixant (BAY 1817080), whic
20 by 1 microM A-317491, a potent and selective P2X3 receptor antagonist.
21  C-fibers), which was inhibited by TRPV4 and P2X3 receptor antagonists.
22             Preclinical studies suggest that P2X3 receptors are expressed by airway vagal afferent ne
23 agonist, A-317491, all indicate that ATP and P2X3 receptors are more likely to be involved in chronic
24                             We conclude that P2X3 receptors are present on both myelinated and unmyel
25 These data support the identification of the P2X3 receptor as a potential new target for the control
26 highlighting the potential for inhibition of P2X3 receptors as a novel anti-arrhythmic.
27                 In contrast, deletion of the P2X3 receptor causes enhanced thermal hyperalgesia in ch
28 m to prevent excessive ATP signaling through P2X3 receptor channels.
29                                     Pirt and P2X3 receptor co-localize in bladder nerve fibres and he
30                 To determine whether ATP and P2X3 receptors contribute to bone-cancer pain in a mouse
31                                              P2X3 receptors could mediate sensitisation of the cough
32                                              P2X3 receptors desensitize within 100 ms of channel acti
33       Mice with genetic deletion of P2X2 and P2X3 receptors (double knockout mice) lack responses to
34 al assays at recombinant rat P2X1, P2X2, and P2X3 receptors expressed in Xenopus oocytes (ion flux st
35                                  We verified P2X3 receptor expression in human carotid bodies and obs
36 d purinergic receptor sensitivity and raised P2X3 receptor expression in the urothelium.
37 ckout mice lacking expression of P2X2 and/or P2X3 receptors failed to show increases in apical surfac
38 o the high affinity (< 1 nM) of desensitized P2X3 receptors for agonist.
39 pha6beta4*) nAChRs and P2X2 receptors and/or P2X3 receptors have not been fully characterized.
40 showed weak antagonistic activity at the rat P2X3 receptor (IC50 58.3 +/- 0.1 microM), while at recom
41 report X-ray crystal structures of the human P2X3 receptor in apo/resting, agonist-bound/open-pore, a
42  ATP currents that are mediated by homomeric P2X3 receptors in dorsal root ganglion (DRG) neurons iso
43 ncy was confirmed by comparing rat and human P2X3 receptors in HEK293 cells.
44  we studied the presence and distribution of P2X3 receptors in human dental pulp, and their co-locali
45                        Interestingly, native P2X3 receptors in rat and monkey DRGs show similar agoni
46 rical stimulation enhances the expression of P2X3 receptors in the membrane and that the enhancement
47                         The interaction with P2X3 receptors is less pronounced for the alpha6beta4bet
48 substitutions at equivalent positions in the P2X3 receptor (Lys63 and Lys299) also prevented channel
49                                              P2X3 receptors may contribute to detection of distention
50               Our data indicate that ATP and P2X3 receptors may play a role in nociception, rather th
51        These results support the theory that P2X3 receptors mediate a form of nociception, but also s
52                            Stellate ganglion P2X3 receptors mediate increases in neuronal intracellul
53  We therefore studied the effects of PGE2 on P2X3 receptor-mediated ATP currents in DRG neurons disso
54             TNFalpha in turn potentiates the P2X3 receptor-mediated responses and increases the excit
55 sis, unbinding of [32P]ATP from desensitized P2X3 receptors mirrored the rate of recovery from desens
56 n the supposed ATP binding site of the human P2X3 receptor on the agonistic effect of nucleotide anal
57  studies demonstrate increased expression of P2X3 receptors on CGRP-ir ENFs during tumor growth and s
58  identify whether changes in the labeling of P2X3 receptors on epidermal nerve fibers (ENFs) occurred
59  a transmitter, ATP, that activates P2X2 and P2X3 receptors on gustatory afferent fibers.
60                  These reports indicate that P2X3 receptors on sensory nerves may be tonically activa
61 ssumption has been that eliminating P2X2 and P2X3 receptors only removes postsynaptic targets but tha
62 e largely abolished in mice lacking P2X2 and P2X3 receptors [P2X2 and P2X3 double knock-out (DKO) mic
63                                          The P2X3 receptor (P2X3R), an ATP-gated cation channel predo
64 d body triggers episodic discharges that via P2X3 receptors play a crucial role in the progression of
65                                ATP-dependent P2X3 receptors play a crucial role in the sensitization
66                                ATP-activated P2X3 receptors play a pivotal role in chronic cough, aff
67 e strong therapeutic rationale for targeting P2X3 receptors, preliminary antagonists have been hamper
68                                   Inhibiting P2X3 receptors rapidly and profoundly recovers normal he
69 lues of 11 and 25 nM at recombinant P2X1 and P2X3 receptors, respectively.
70 rgic, placodal in origin, expresses P2X2 and P2X3 receptors, responds to alpha,beta-methylene ATP, an
71                                              P2X3 receptors seem to have a key role in mediation of c
72      Coexpression of alpha6beta4 nAChRs with P2X3 receptors shifts the ATP dose-response relation to
73                               Antagonists of P2X3 receptors such as AF-219 are a promising new group
74 nusual subtype of ATP-gated ion channel, the P2X3 receptor, that rapidly desensitizes (<100 msec) and
75                                  In 1995 the P2X3 receptor was found to be expressed at high levels i
76 l evidence showed that immunostaining of the P2X3 receptors was more intense in both IB4-positive (C-
77                Western blot data showed that P2X3 receptors were significantly upregulated in doral r
78                                  Purinergic (P2X3) receptors were upregulated two-fold in peripheral
79                                              P2X3 receptors with an equivalent mutation (P320C) were